Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2010-2019 |
| Journal | Multiple Sclerosis Journal |
| Volume | 28 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - 1 Nov 2022 |
Funding
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.H. receives research support from the Dutch MS Research Foundation. L.E.J. receives research support from Alzheimer Association, Alzheimer Netherlands, Michael J Fox Foundation, Stichting ParkinsonFonds, and Health Holland. H.E.H. receives research support from Dutch MS Research Foundation, ZonMW, NWO, ATARA, Biogen, Celgene/BMS, Merck, and MedDay; serves as a consultant for Sanofi Genzyme, Merck BV, Biogen Idec, Roche, and Novartis; and is on the editorial board of Multiple Sclerosis Journal. M.M.S. serves as an editorial board member of Frontiers in Neurology, received research support from the Dutch MS Research Foundation ARSEP, Eurostars-EUREKA, ZonMW, Amsterdam Neuroscience, Atara, Biogen, Celgene/BMS, Merck, and MedDay; and received consulting or speaking fees from ExceMed, Genzyme, Novartis, and Biogen. J.J.G.G. has served as a consultant for Merck-Serono, Biogen, Novartis, Genzyme, and Teva Pharmaceuticals; he has received research support from the Dutch MS Research Foundation, Ammodo, Eurostars-EUREKA, Biogen, Celgene/BMS, Merck, MedDay, and Novartis. Other authors report no competing interests. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Dutch MS Research Foundation (grant nos. 14-358e and 16-954b), and MoveS foundation.
| Funders | Funder number |
|---|---|
| Dutch MS Research Foundation | 14-358e, 16-954b |
| Dutch MS Research Foundation ARSEP | |
| MoveS foundation | |
| Michael J. Fox Foundation for Parkinson's Research | |
| Alzheimer's Association | |
| Merck | |
| Novartis | |
| Biogen | |
| Teva Pharmaceutical Industries | |
| Health~Holland | |
| ZonMw | |
| Alzheimer Nederland |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver